Podcast appearances and mentions of david sallman

Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Anemia presents a significant challenge in the management of patients with low-risk myelodysplastic syndromes (MDS). Given the considerable potential for symptom burden associated with anemia in patients with MDS, health care professionals must prioritize enhancing quality of life when evaluating treatment options. In this episode, CANCER BUZZ speaks with David Sallman, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center, and Karley Trautman, DNP, ANP-BC, AGACNP-BC, senior instructor of Medical Oncology at Highlands Ranch Cancer Center, to discuss best practices in the management of anemia in low-risk MDS patients.  “The goal is still personalizing [treatment] for the patient. So say a patient feel[s] better when their hemoglobin is greater than 10 grams per deciliter, as an example. So you titrate or transition therapies until you achieve that…in order to make the patient's experience better.”—David Sallman, MD   “Two people that have the same hemoglobin level can have completely different symptoms. So it's really important that we don't just focus on the numbers, but we focus on how the patient is feeling and how they're functioning…so that if they're doing well, even at a lower number than something we might typically treat, we don't let that number drive how often we feel like they need to be seen, but we take it into account—[treating] the whole person.”—Karley Trautman, DNP, ANP-BC, AGACNP-BC   David Sallman, MD Associate Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL   Karley Trautman, DNP, ANP-BC, AGACNP-BC Senior Instructor, Medical Oncology Highlands Ranch Cancer Center Denver, CO   This episode was developed in connection with the ACCC education initiative Anemia Mitigation & Optimal Care for MDS Patients and is supported by Bristol Myers Squibb.   Resources: ACCC Myelodysplastic Syndromes  ASH 2020 Treatment Algorithm Lower-Risk MDS 

Anemia can negatively affect quality of life and treatment outcomes for patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia. In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, director, Bone Marrow Failure and MDS Program, Johns Hopkins University School of Medicine in Baltimore, Maryland, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, clinical oncology pharmacy manager, Atrium Health Levine Cancer in Charlotte, North Carolina, and David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center in Tampa, Florida. Their discussion elucidates an array of patient-centered approaches, touches on social determinants of health, and highlights collaborative measures to support care coordination in the management of anemia in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.   “It really does take a village to manage the anemia of high-risk MDS…We as providers need to think through transfusion mitigation strategies but also keep our patients safe.” –Amy DeZern, MD, MHS   “Health disparities can play a really important role in affecting outcomes. And a lot of that is multifactorial—it may be due to patients without insurance having a higher tendency to delay seeking care due to the associated cost of seeking medical attention, and therefore they may present sicker.”—Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP “There's no question, especially as therapies are getting more complex, and the side effects as far as the severity of cytopenias are increasing, this collaboration between blood bank centers and community oncologists is going to be increasingly important.”—David Sallman, MD Amy DeZern, MD, MHS Director, Bone Marrow Failure and MDS Program Professor of Oncology and Medicine Johns Hopkins University School of Medicine Baltimore, MD   Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Charlotte, NC   David Sallman, MD Assistant Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida   This episode was developed in connection with an initiative of the ACCC education program Myelodyplastic Syndromes, Optimal Management of Anemia in Adults with High-Risk MDS, which is supported by Gilead.   Resources: Myelodysplastic Syndromes - ACCC Achieving & Maintaining Better Outcomes for Patients with Acute Myeloid Leukemia Project - ACCC Disparities in Acute Myeloid Leukemia - ACCC  

Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, including the following topics: Introduction (00:00) Biology of Acute Myeloid Leukemia/Myelodysplastic Syndromes (3:14) Assessment of Risk Status (14:17) Oral Hypomethylating Agents (HMAs) (22:24) HMA/Venetoclax; Other Combinations (31:26) Magrolimab/TP53 (45:12) CME information and select publications  

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes — Faculty Presentation 2: Future directions in the management of higher-risk MDS  — Dr David Sallman CME information and select publications

Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman. CME information and select publications here (https://www.researchtopractice.com/InsidetheIssue2023/MDS)

Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, moderated by Dr Neil Love.

A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new study, David Sallman, MD, from the Moffitt Cancer Center in Tampa, Florida, had reported the new findings at the 2022 Annual Meeting of the American Society of Hematology, OncTimes Talk correspondent Peter Goodwin interviewed him about the study and about the overall prospects of using CAR-T cells to treat AML. PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (CAR)-T simultaneously expressing a CAR specifically targeting CD33; membrane bound IL-15 (mbIL15) for enhanced in vivo expansion and persistence; and a kill switch to conditionally eliminate CAR-T cells for an improved safety profile. CD33 is over-expressed on AML blasts with lesser expression on normal hematopoietic stem cells. PRGN-3006 UltraCAR-T drug product is manufactured via an overnight process at medical centers using the Company's proprietary non-viral and UltraPorator systems and released for infusion in patients the next day. The decentralized, overnight UltraCAR-T manufacturing process, which does not use viral vectors or ex vivo activation and expansion of T cells, has the potential to address major limitations of current T cell therapies. PRGN-3006 UltraCAR-T has been granted Orphan Drug Designation and Fast Track Designation in patients with AML by the FDA. The Phase I/Ib clinical study is designed to enroll in two phases, an initial dose escalation phase followed by a dose expansion phase, to evaluate safety and determine the recommended Phase II dose of PRGN-3006 delivered via intravenous (IV) infusion without lymphodepletion (Cohort 1) or with lymphodepletion (Cohort 2). The study is also evaluating in vivo persistence and anti-tumor activity of PRGN-3006.

Featuring perspectives from Drs Guillermo Garcia-Manero, Gail Roboz and David Sallman, including the following topics: Prologue: A vision for the future (0:00) Classification and prognosis of myelodysplastic syndromes (MDS) (23:34) Current management of lower-risk MDS (25:57) Current management of higher-risk MDS (38:16) MDS-Acute Myeloid Leukemia continuum and overlap: Venetoclax and other targeted therapy (46:38) CME information and select publications

Featuring perspectives from Drs Guillermo Garcia-Manero, Gail Roboz and David Sallman, moderated by Dr Neil Love.

CME credits: 0.25 Valid until: 31-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-with-hematologic-malignancies-understanding-classifying-and-stratifying-mds/13282/ In order to effectively treat the MDS patient in front of us, we first need to classify their disease and understand its risk stratification category. Hear what Dr. David Sallman and Dr. Jacqueline Garcia have to say about MDS prognosis and risk stratification to better understand each patient's disease progression.

CME credits: 0.25 Valid until: 31-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-with-hematologic-malignancies-understanding-classifying-and-stratifying-mds/13282/ In order to effectively treat the MDS patient in front of us, we first need to classify their disease and understand its risk stratification category. Hear what Dr. David Sallman and Dr. Jacqueline Garcia have to say about MDS prognosis and risk stratification to better understand each patient's disease progression.

Bernard E et al: In the first presented study, Dr. Elza Bernard and colleagues deliver an important lesson about the high-risk mutation TP53. That is: not all of them are infeed associated with poor prognosis.Sallman DA et al:A recent study led by Dr. David Sallman tested the efficacy of the combination azacitidine and eprenetapopt (formerly APR-246), a TP53-Mutant activator, in patients with higher-risk MDS.Goll JB et al:One of the more interesting presentations in the last ASH 2020, was that of Dr. Yohannes Goll and others. They showed that adding molecular analysis they can improve the diagnostic accuracy. Indeed 7 genes significantly reduced pathological misclassification.Platzbecker U et al:A group of international investigators, led by Dr. Uwe Platzbecker, from Leipzig, reported in last ASH (2020) their encouraging experience with imetelstat, a telomerase-inhibitor to improve anemia in lower-risk MDS patients after ESA failure.

A special audio program developed from a series of webinars held in conjunction with the Society of Hematologic Oncology 2021 Annual Meeting. Featuring case presentations from Drs Courtney D DiNardo, Daniel A Pollyea, David Sallman and Eunice S Wang.

Featuring case presentations from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics: Case: A woman in her mid-80s with newly diagnosed acute myeloid leukemia (AML) — Daniel A Pollyea, MD, MS (0:00) Case: A man in his early 70s with AML and a complex monosomal karyotype — Dr Pollyea (4:02) Case: A woman in her mid-70s with newly diagnosed AML with trisomy 21 and AXLS1 and RUNX1 mutations — Dr Pollyea (5:22) Case: A woman in her late 70s with AML and a FLT3-ITD mutation — Courtney D DiNardo, MD, MSCE (7:41) Case: A man in his late 70s with AML and diploid cytogenetics — Dr DiNardo (11:46) Case: A man in his mid-60s with secondary AML and DNMT3A and FLT3-ITD mutations — Eunice S Wang, MD (17:33) Case: A woman in her late 60s with lower-risk myelodysplastic syndrome (MDS) — David Sallman, MD (25:55) Case: A man in his late 70s with high-risk MDS — Dr Sallman (29:26) CME information and select publications

Featuring slide presentations and related discussion from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics: Treatment Options for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) without Targetable Mutations — Daniel A Pollyea, MD, MS (0:00) Optimal Management of AML with Targetable Mutations — Courtney D DiNardo, MD, MSCE (28:03) Other Currently Available and Investigation Treatment Strategies for AML — Eunice S Wang, MD (49:37) Current and Future Therapeutic Approaches for Patients with Myelodysplastic Syndromes (MDS) — David Sallman, MD (1:28:55) CME information and select publications  

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Drs Mark Levis and David Sallman, including the following topics: Introduction Challenge of New Treatment Options for AML; Role of CPX-351 — Dr Peles Hypomethylating Agents/Venetoclax: Appropriate Candidates, Tolerability and Dose Adjustments — Dr Kumar Personal Experience with Administering Azacitidine/Venetoclax — Dr Choksi Approach to Treatment-Associated Adverse Events After the First Cycle of Venetoclax/HMA in Patients with AML Chalk Talk — Dr Sallman (Part 1) Case: A woman in her late 60s with AML — Dr Gandhi Appropriate Use of Antifungal Agents for Patients Receiving Venetoclax — Dr Apuri Role of FLT3 and IDH1/2 Inhibitors for Patients Who Are Ineligible for Intensive Induction Therapy — Dr Peles Up-Front Management of AML in Older Patients with an IDH Mutation Who Are Not Eligible for Intensive Therapy Chalk Talk — Dr Sallman (Part 2) Management of Secondary AML in Younger Patients Chalk Talk — Dr Levis (Part 1) Case: A woman in her early 80s initially treated for idiopathic thrombocytopenic purpura — Ferdy Santiago, MD Case: A woman in her late 80s with low-grade myelodysplastic syndromes with ringed sideroblasts — Dr Apuri Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Chalk Talk — Dr Levis (Part 2) CME information and select publications  

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

A special audio program developed from a series of webinars held in conjunction with the Society of Hematologic Oncology 2021 Annual Meeting. Featuring perspectives from Drs Courtney D DiNardo, Daniel A Pollyea, David Sallman and Eunice S Wang.

Featuring perspectives from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics: Introduction (0:00) Prologue: A Personal Reflection on Acute Myeloid Leukemia (AML) (1:01) Case: A woman in her mid-80s with newly diagnosed AML — Daniel A Pollyea, MD, MS (8:28) Up-Front Treatment of AML in Patients Who Are Not Eligible for Intensive Therapy (11:54) Case: A man in his early 70s with AML and a complex monosomal karyotype — Dr Pollyea (24:32) Management of AML with Targetable Mutations (33:14) Case: A woman in her late 70s with AML and a FLT3-ITD mutation — Courtney D DiNardo, MD, MSCE (40:04) Case: A man in his late 70s with AML and diploid cytogenetics — Dr DiNardo (48:41) Other Currently Available and Investigational Treatment Strategies for AML (51:57) Case: A man in his mid-60s with secondary AML and DNMT3A and FLT3-ITD mutations — Eunice S Wang, MD (54:50) Case: A woman in her late 50s with leukemia cutis — Dr Wang (1:06:25) Case: A woman in her late 60s with lower-risk myelodysplastic syndrome (MDS) — David Sallman, MD (1:09:20) Case: A man in his late 70s with high-risk MDS — Dr Sallman (1:15:37) Case: A man in his mid-80s with high-risk MDS — Dr Sallman (1:22:27) CME information and select publications

Bernard E et al: In the first presented study, Dr. Elza Bernard and colleagues deliver an important lesson about the high-risk mutation TP53. That is: not all of them are infeed associated with poor prognosis. Sallman DA et al:A recent study led by Dr. David Sallman tested the efficacy of the combination azacitidine and eprenetapopt (formerly APR-246), a TP53-Mutant activator, in patients with higher-risk MDS. Goll JB et al:One of the more interesting presentations in the last ASH 2020, was that of Dr. Yohannes Goll and others. They showed that adding molecular analysis they can improve the diagnostic accuracy. Indeed 7 genes significantly reduced pathological misclassification. Platzbecker U et al:A group of international investigators, led by Dr. Uwe Platzbecker, from Leipzig, reported in last ASH (2020) their encouraging experience with imetelstat, a telomerase-inhibitor to improve anemia in lower-risk MDS patients after ESA failure.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia